Why the study?
Does rivaroxaban 2.5 mg twice daily improve efficacy and safety outcomes in acute coronary syndrome patients?
Does rivaroxaban 2.5 mg twice daily improve efficacy and safety outcomes in acute coronary syndrome patients?
Rivaroxaban 2.5 mg twice daily is an effective and safe anticoagulation strategy in acute coronary syndrome, supported by European and Russian guidelines.
Answers are grounded in this paper and cite their sources.
May support guideline-directed use in ACS; leaves open need for updated comparative trials.
The analytical article focuses on the data concerning duration of anticoagulation treatment in acute coronary syndrome patients. The information provided on the evidence for impossibility of widespread usage of vitamin K antagonists in acute coronary syndrome — the novel selective oral anticoagulants that differ from rivaroxaban. The main evidence is showed for efficacy and safety of rivaroxaban in acute coronary syndrome, conditions of its application and fundamentals for dosage selection as 2,5 mg two times per day. European and Russian Guidelines arepresented that permit usage of rivaroxaban in acute coronary syndrome.
No takes yet. Share an insight, caveat, or question.
О. В. Аверков (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: